The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD). This is a non-randomized, observational, non-treatment study that originally launched in 2015, enrolling 133 participants. From the originally enrolled participants, the continuation of the ADNI-D study will enroll 120 participants which will include following participants from the original (parent) protocol and enrollment of new participants for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison. Depression history, symptom severity and health information will be collected at the initial visit to determine eligibility. An magnetic resonance imaging (MRI) scan, as well as amyloid (florbetapir) and tau (flortaucipr) positron emission tomography (PET) imaging will be conducted at San Francisco VA. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Rate of Change in neuropsychological measures of executive function as measured by the Digit Symbol Substitution Test using total correct.
Timeframe: 5 years (parent protocol), 5 years (continuation)
Rate of Change in expressive language as measured by the Boston Naming Test using total correct.
Timeframe: 5 years (parent protocol), 5 years (continuation)
Rate of change in learning and memory as measured by the Rey Auditory Verbal Learning Test using total correct and delayed recall.
Timeframe: 5 years (parent protocol), 5 years (continuation)
Change in brain structure using magnetic resonance imaging (MRI)
Timeframe: 5 years (parent protocol), 5 years (continuation)
Extent of amyloid deposition as measured by florbetapir
Timeframe: 5 years (parent protocol), 5 years (continuation)
Extent of tau deposition as measured by flortaucipr
Timeframe: 5 years (continuation)